Equillium Financials
This page shows Equillium (EQ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Equillium has an operating margin of -57.5%, meaning the company retains $-58 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -20.1% the prior year.
Equillium's revenue grew a modest 0.0% year-over-year to $41.1M. This slow but positive growth earns a score of 33/100.
Equillium carries a low D/E ratio of 0.12, meaning only $0.12 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 10.58, Equillium holds $10.58 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Equillium generated -$22.7M in operating cash flow, capex of $48K consumed most of it, leaving -$22.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Equillium generates a -78.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -42.3% the prior year.
Equillium passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Equillium generates $1.02 in operating cash flow (-$22.7M OCF vs -$22.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Equillium generated $41.1M in revenue in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Equillium's EBITDA was -$23.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 189.2% from the prior year.
Equillium reported -$22.4M in net income in fiscal year 2025. This represents a decrease of 177.6% from the prior year.
Equillium earned $-0.39 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 69.6% from the prior year.
Cash & Balance Sheet
Equillium generated -$22.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 19.3% from the prior year.
Equillium held $30.3M in cash against $0 in long-term debt as of fiscal year 2025.
Equillium had 63M shares outstanding in fiscal year 2025. This represents an increase of 77.8% from the prior year.
Margins & Returns
Equillium's operating margin was -57.5% in fiscal year 2025, reflecting core business profitability. This is down 37.4 percentage points from the prior year.
Equillium's net profit margin was -54.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 34.9 percentage points from the prior year.
Equillium's ROE was -78.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 36.0 percentage points from the prior year.
Capital Allocation
Equillium invested $400K in research and development in fiscal year 2025. This represents a decrease of 98.9% from the prior year.
Equillium invested $48K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 43.5% from the prior year.
EQ Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $4.4M-63.9% | $12.2M-12.2% | $13.9M+29.6% | $10.7M+16.0% | $9.2M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.3M-68.1% | $4.1M-31.1% | $5.9M-19.0% | $7.3M-23.5% | $9.6M-11.5% | $10.8M+10.9% | $9.7M+6.1% | $9.2M |
| SG&A Expenses | $3.3M+52.6% | $2.1M-27.2% | $2.9M+65.9% | $1.8M-45.8% | $3.3M+4.2% | $3.1M-15.8% | $3.7M+15.8% | $3.2M |
| Operating Income | -$4.6M+26.5% | -$6.2M+29.8% | -$8.9M-88.8% | -$4.7M-592.0% | -$679K-579.0% | -$100K+96.4% | -$2.8M+12.8% | -$3.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | $0-100.0% | $361K | $0 | $0 | $0-100.0% | $16K |
| Net Income | -$4.2M+26.3% | -$5.7M+33.7% | -$8.7M-49.4% | -$5.8M-82671.4% | -$7K-101.5% | $468K+117.1% | -$2.7M-16.7% | -$2.3M |
| EPS (Diluted) | $-0.06+62.5% | $-0.16+33.3% | $-0.24 | N/A | $0.00-100.0% | $0.01+112.5% | $-0.08 | N/A |
EQ Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $34.5M+178.3% | $12.4M-25.9% | $16.7M-34.7% | $25.6M-25.7% | $34.5M-19.6% | $42.9M-1.7% | $43.6M-13.7% | $50.5M |
| Current Assets | $33.6M+180.9% | $12.0M-26.3% | $16.2M-35.1% | $25.0M-25.8% | $33.6M-19.7% | $41.9M-1.4% | $42.5M-13.9% | $49.3M |
| Cash & Equivalents | $33.1M+188.1% | $11.5M-20.7% | $14.5M-19.8% | $18.1M+17.1% | $15.4M+39.7% | $11.1M-4.4% | $11.6M-50.2% | $23.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | $0-100.0% | $5.0M-15.0% | $5.9M+16.7% | $5.0M+35.2% | $3.7M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.6M-51.4% | $7.3M+19.4% | $6.2M-6.0% | $6.5M-42.0% | $11.3M-44.8% | $20.4M-9.2% | $22.5M-19.5% | $28.0M |
| Current Liabilities | $3.1M-57.2% | $7.2M+20.5% | $6.0M-5.6% | $6.4M-42.5% | $11.1M-45.2% | $20.2M-9.2% | $22.2M-19.5% | $27.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $30.9M+511.9% | $5.1M-52.2% | $10.6M-44.5% | $19.1M-17.8% | $23.2M+3.3% | $22.4M+6.3% | $21.1M-6.6% | $22.6M |
| Retained Earnings | -$212.4M-2.0% | -$208.2M-2.8% | -$202.5M-4.5% | -$193.8M-3.1% | -$188.0M0.0% | -$188.0M+0.2% | -$188.5M-1.5% | -$185.7M |
EQ Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.4M-179.8% | -$3.0M+63.1% | -$8.2M-147.6% | -$3.3M+56.9% | -$7.7M-1148.9% | $730K+108.3% | -$8.8M-55.4% | -$5.7M |
| Capital Expenditures | $0 | $0-100.0% | $4K0.0% | $4K | $0-100.0% | $62K+226.3% | $19K-45.7% | $35K |
| Free Cash Flow | -$8.4M-179.8% | -$3.0M+63.1% | -$8.2M-147.4% | -$3.3M+56.9% | -$7.7M-1246.3% | $668K+107.6% | -$8.8M-54.7% | -$5.7M |
| Investing Cash Flow | $0 | $0-100.0% | $4.5M-25.0% | $6.0M-50.0% | $12.0M+988.2% | -$1.4M+52.3% | -$2.8M+49.1% | -$5.6M |
| Financing Cash Flow | $30.1M+188031.3% | -$16K-117.6% | $91K+24.7% | $73K | $0 | N/A | N/A | $79K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
EQ Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | -107.0%-101.4pp | -5.6%-4.9pp | -0.7%+25.4pp | -26.1%+8.6pp | -34.7% |
| Net Margin | N/A | N/A | N/A | -131.9%-131.9pp | -0.1%-3.4pp | 3.4%+29.0pp | -25.6%-0.2pp | -25.4% |
| Return on Equity | -13.7%+99.8pp | -113.5%-31.7pp | -81.8%-51.4pp | -30.4%-30.4pp | -0.0%-2.1pp | 2.1%+15.0pp | -13.0%-2.6pp | -10.4% |
| Return on Assets | -12.3%+34.0pp | -46.3%+5.4pp | -51.7%-29.1pp | -22.6%-22.6pp | -0.0%-1.1pp | 1.1%+7.4pp | -6.3%-1.6pp | -4.6% |
| Current Ratio | 10.85+9.2 | 1.65-1.0 | 2.70-1.2 | 3.93+0.9 | 3.04+1.0 | 2.08+0.2 | 1.91+0.1 | 1.79 |
| Debt-to-Equity | 0.12-1.3 | 1.45+0.9 | 0.58+0.2 | 0.34-0.1 | 0.49-0.4 | 0.91-0.2 | 1.07-0.2 | 1.24 |
| FCF Margin | N/A | N/A | N/A | -75.2%-12.2pp | -63.0%-67.8pp | 4.8%+87.3pp | -82.5%-20.6pp | -61.9% |
Similar Companies
Frequently Asked Questions
What is Equillium's annual revenue?
Equillium (EQ) reported $41.1M in total revenue for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Equillium's revenue growing?
Equillium (EQ) revenue grew by 0% year-over-year, from $41.1M to $41.1M in fiscal year 2025.
Is Equillium profitable?
No, Equillium (EQ) reported a net income of -$22.4M in fiscal year 2025, with a net profit margin of -54.5%.
What is Equillium's EBITDA?
Equillium (EQ) had EBITDA of -$23.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Equillium's operating margin?
Equillium (EQ) had an operating margin of -57.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Equillium's net profit margin?
Equillium (EQ) had a net profit margin of -54.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Equillium's return on equity (ROE)?
Equillium (EQ) has a return on equity of -78.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Equillium's free cash flow?
Equillium (EQ) generated -$22.8M in free cash flow during fiscal year 2025. This represents a -19.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Equillium's operating cash flow?
Equillium (EQ) generated -$22.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Equillium's total assets?
Equillium (EQ) had $31.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Equillium's capital expenditures?
Equillium (EQ) invested $48K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Equillium spend on research and development?
Equillium (EQ) invested $400K in research and development during fiscal year 2025.
What is Equillium's current ratio?
Equillium (EQ) had a current ratio of 10.58 as of fiscal year 2025, which is generally considered healthy.
What is Equillium's debt-to-equity ratio?
Equillium (EQ) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Equillium's return on assets (ROA)?
Equillium (EQ) had a return on assets of -70.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Equillium's cash runway?
Based on fiscal year 2025 data, Equillium (EQ) had $30.3M in cash against an annual operating cash burn of $22.7M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Equillium's Piotroski F-Score?
Equillium (EQ) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Equillium's earnings high quality?
Equillium (EQ) has an earnings quality ratio of 1.02x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Equillium?
Equillium (EQ) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.